stoxline Quote Chart Rank Option Currency Glossary
  
Allogene Therapeutics, Inc. (ALLO)
3.08  0.19 (6.57%)    07-23 16:00
Open: 2.86
High: 3.105
Volume: 2,074,922
  
Pre. Close: 2.89
Low: 2.82
Market Cap: 643(M)
Technical analysis
2024-07-23 4:50:20 PM
Short term     
Mid term     
Targets 6-month :  4.28 1-year :  5
Resists First :  3.67 Second :  4.28
Pivot price 2.69
Supports First :  2.64 Second :  2
MAs MA(5) :  3.05 MA(20) :  2.61
MA(100) :  3.28 MA(250) :  3.41
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  55.6 D(3) :  58.7
RSI RSI(14): 59.1
52-week High :  5.78 Low :  2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ALLO ] has closed below upper band by 28.8%. Bollinger Bands are 84.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.11 - 3.13 3.13 - 3.14
Low: 2.79 - 2.8 2.8 - 2.82
Close: 3.05 - 3.08 3.08 - 3.11
Company Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Headline News

Thu, 18 Jul 2024
Allogene Therapeutics (NASDAQ:ALLO) Sees Large Volume Increase - American Banking and Market News

Tue, 02 Jul 2024
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News

Thu, 27 Jun 2024
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? - Yahoo Finance

Fri, 17 May 2024
Watkins Advises Allogene Therapeutics in Pricing of US$110 Million Offering of Common Stock - Latham & Watkins LLP -

Mon, 13 May 2024
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update - Yahoo Finance

Mon, 13 May 2024
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 209 (M)
Held by Insiders 1.2456e+008 (%)
Held by Institutions 17.5 (%)
Shares Short 40,570 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.7066e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -315 %
Return on Assets (ttm) 927.2 %
Return on Equity (ttm) -26.8 %
Qtrly Rev. Growth 87000 %
Gross Profit (p.s.) -31.42
Sales Per Share -65.28
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -227 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -2.3
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 0.96
Stock Dividends
Dividend 0
Forward Dividend 4.138e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android